209 related articles for article (PubMed ID: 3929677)
1. Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.
Goldstein EJ; Citron DM
Antimicrob Agents Chemother; 1985 Jul; 28(1):160-2. PubMed ID: 3929677
[TBL] [Abstract][Full Text] [Related]
2. Population analysis in strains of Staphylococcus aureus and Staphylococcus epidermidis. II. Cefuroxime and cefotaxime.
Hansen BG
Acta Pathol Microbiol Immunol Scand B; 1983 Dec; 91(6):425-9. PubMed ID: 6324530
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory and bactericidal activity of cefpirome and cefotaxime against blood culture isolates.
Ansorg R; Primavesi CA; von Recklinghausen G
Chemotherapy; 1990; 36(1):24-8. PubMed ID: 2106417
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo activity of cefpirome (HR 810) against methicillin-susceptible and -resistant Staphylococcus aureus and Streptococcus faecalis.
Eng RH; Cherubin CE; Smith SM; Buccini F; Harris R
J Antimicrob Chemother; 1989 Mar; 23(3):373-81. PubMed ID: 2499565
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Higashi Y; Kamimura T; Matsumoto Y; Tawara S; Matsumoto F
J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562
[TBL] [Abstract][Full Text] [Related]
6. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.
Corser CA; Day GJ; Humble MW
N Z Med J; 1982 Jun; 95(710):414-6. PubMed ID: 6810246
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activity and beta-lactamase stability of CL 118523, an aminothiazolyl iminomethoxy cephalosporin.
Chin NX; Neu HC
Chemioterapia; 1987 Oct; 6(5):329-36. PubMed ID: 3322588
[TBL] [Abstract][Full Text] [Related]
8. Activity of cefpirome combined with beta-lactamase inhibitors and affinity for the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus.
Piddock LJ; Traynor EA; Griggs DJ
Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):364-71. PubMed ID: 1396760
[TBL] [Abstract][Full Text] [Related]
9. The in-vitro activity of ceftazidime against clinically important pathogens.
Knothe H; Dette GA
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():33-41. PubMed ID: 19810167
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method.
Hoogkamp-Korstanje JA; Meijer CA
Eur J Clin Microbiol; 1982 Jun; 1(3):166-70. PubMed ID: 6293813
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of BMY-28142, a new cephalosporin.
Norden CW; Neiderriter K
Chemotherapy; 1987; 33(1):15-7. PubMed ID: 3103990
[TBL] [Abstract][Full Text] [Related]
12. Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria.
Venezio FR; Tatarowicz W; DiVincenzo CA; O'Keefe JP
Antimicrob Agents Chemother; 1986 Dec; 30(6):940-1. PubMed ID: 3101589
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime: comparative in-vitro study.
Verbist L; Verhaegen J
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():67-71. PubMed ID: 19802971
[TBL] [Abstract][Full Text] [Related]
14. [In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):567-71. PubMed ID: 3534744
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial properties of imipenem with special reference to the activity against methicillin-resistant staphylococci, cefotaxime-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Vurma-Rapp U; Kayser FH; Barberis-Maino L
J Antimicrob Chemother; 1986 Dec; 18 Suppl E():27-33. PubMed ID: 3102452
[TBL] [Abstract][Full Text] [Related]
16. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
[TBL] [Abstract][Full Text] [Related]
17. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
van Klingeren B
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of HR 810, a new broad-spectrum cephalosporin.
Machka K; Braveny I
Eur J Clin Microbiol; 1983 Aug; 2(4):345-9. PubMed ID: 6313358
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
20. The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus.
Seibert G; Isert D; Klesel N; Limbert M; Markus A; Schrinner E
J Antimicrob Chemother; 1992 Apr; 29 Suppl A():25-30. PubMed ID: 1601753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
